Assessment of Retrospective Analysis Results for the Use of Leflunomide in Chronic Sarcoidosis
https://doi.org/10.31550/1727-2378-2022-21-6-49-53
Abstract
Study Objective: To assess the efficacy and safety of the use of leflunomide (LF) in chronic present and/or refractory sarcoidosis.
Study Design: Retrospective observational non-interventional analysis.
Materials and Methods. We studied the use of LF (20 mg daily) in 15 out of 1470 (1.0%) patients included into the State Sarcoidosis Clinical Database. The group included 11 female and 4 male patients aged 30 to 60 years old. 2 patients had X-ray stage I disease, 11 patients had stage II, 1 patient had stage III, and 1 patient had stage IV. All patients had histologically-proven diagnosis. We assessed the clinical condition of the patients as well as laboratory and functional data. We used SPSS-18 for statistical processing. Study Results. Stable and improved condition on a visual analogue scale was noted in 93.3% of patients. As for the forced vital respiratory capacity, a positive response was 80.0% (improvement in one out of four patient); on the ray pattern, the improvement was 934% (improvement in 66.7% of patients). Good LF tolerability was recorded in 6 patients, 7 patients reported adverse reactions which did not result in treatment discontinuation; and 2 patients discontinued the therapy in 3 months due to sacred fire which was successfully treated with antibiotics (n = 1), nausea, vomiting, and diarrhoea (n = 1).
Conclusion. According to the results, LF can be used as a second or third line of therapy in chronic and/or refractory sarcoidosis.
About the Authors
A. A. VizelRussian Federation
49 Butlerov Str., Kazan, 420012
I. Yu. Vizel
Russian Federation
49 Butlerov Str., Kazan, 420012
G. R. Shakirova
Russian Federation
49 Butlerov Str., Kazan, 420012
138 Orenburg trakt, Kazan, 420064
References
1. Goldman C., Judson M.A. Corticosteroid refractory sarcoidosis. Respir. Med. 2020; 171: 106081. DOI: 10.1016/j.rmed.2020.106081
2. Perlman D.M., Sudheendra M.T., Furuya Y. et al. Clinical presentation and treatment of high-risk sarcoidosis. Ann. Am. Thorac. Soc. 2021; 18(12): 1935–47. DOI: 10.1513/AnnalsATS.202102-212CME
3. Baughman R.P., Valeyre D., Korsten P. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur. Respir. J. 2021; 58(6): 2004079. DOI: 10.1183/13993003.04079-2020
4. Otto-Ślusarczyk D., Graboń W., Mielczarek-Puta M. et al. Teriflunomide — The common drug with underestimated oxygen — Dependent anticancer potential. Biochem. Biophys. Rep. 2021; 28: 101141. DOI: 10.1016/j.bbrep.2021.101141
5. Vizel A.A., Vizel I.Yu. Leflunomide as a potential second-line drug in the treatment of sarcoidosis. Tuberculosis and Lung Diseases. 2019; 97(8): 52–8. (in Russian). DOI: 10.21292/2075-1230-2019-97-8-52-58
6. Baughman R.P., Barriuso R., Beyer K. et al. Sarcoidosis: patient treatment priorities. ERJ Open Res. 2018; 4(4): 00141–2018. DOI: 10.1183/23120541.00141-2018
7. Baughman R.P., Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2004; 21(1): 43–8. DOI: 10.1007/s11083-004-5178-y
8. Sahoo D.H., Bandyopadhyay D., Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur. Respir. J. 2011; 38(5): 1145–50. DOI: 10.1183/09031936.00195010
9. Miedema J.R., Bonella F., Grunewald J. et al. Looking into the future of sarcoidosis: what is next for treatment? Curr. Opin. Pulm. Med. 2020; 26(5): 598–607. DOI: 10.1097/MCP.0000000000000709
Review
For citations:
Vizel A.A., Vizel I.Yu., Shakirova G.R. Assessment of Retrospective Analysis Results for the Use of Leflunomide in Chronic Sarcoidosis. Title. 2022;21(6):49-53. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-6-49-53